HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 290/2/R405    most recent 00440.2005v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Meyer, L. C. R. Articles by Mitchell, D. Search for Related Content PubMed PubMed Citation Articles by Meyer, L. C. R. Articles by Mitchell, D.

ENVIRONMENTAL, EXERCISE AND RESPIRATORY PHYSIOLOGY

Zacopride and 8-OH-DPAT reverse opioid-induced respiratory depression and hypoxia but not catatonic immobilization in goats

Brain Function Research Unit, School of Physiology, University of the Witwatersrand, Johannesburg, South Africa

Submitted 22 June 2005 ; accepted in final form 13 September 2005

Neurophysiological studies have shown that serotonergic ligands that bind to 5-HT_1A, 5-HT₇, and 5-HT₄ serotonin receptors in brain stem have beneficial effects on respiratory neurons during opioid-induced respiratory depression. The effect of these ligands on respiratory function and pulmonary performance has not been studied. We therefore examined the effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), an agonist of 5-HT_1A and 5-HT₇ receptors, and zacopride, an agonist of 5-HT₄ receptors, to establish whether these ligands would reverse opioid-induced respiratory depression and hypoxia without affecting the immobilizing properties of the opioid drug etorphine. When etorphine was used to sedate and immobilize goats, it significantly decreased respiratory rate (P = 0.013), percent hemoglobin oxygen saturation (P < 0.0001), and arterial oxygen partial pressure [Pa_O2; F_(10,70) = 5.67, P < 0.05] and increased arterial carbon dioxide partial pressure [F_(10,70) = 3.87, P < 0.05] and alveolar-arterial oxygen partial pressure gradient [A-a gradients; F_(10,70) = 8.23, P < 0.0001]. Zacopride and 8-OH-DPAT, coadministered with etorphine, both attenuated the effects of etorphine; respiration rates did not decrease, and percent hemoglobin oxygen saturation and Pa_O2 remained elevated. Zacopride decreased the hypercapnia, indicating an improvement in ventilation, whereas 8-OH-DPAT did not affect the hypercapnia and, therefore, did not improve ventilation. The main beneficial effect of 8-OH-DPAT was on the pulmonary circulation; it improved oxygen diffusion, indicated by the normal A-a gradients, presumably by improving ventilation perfusion ratios. Neither zacopride nor 8-OH-DPAT reversed etorphine-induced catatonic immobilization. We conclude that serotonergic drugs that act on 5-HT_1A, 5-HT₇, and 5-HT₄ receptors reverse opioid-induced respiratory depression and hypoxia without reversing catatonic immobilization.

serotonin; etorphine; ventilation; alveolar-arterial oxygen partial pressure gradients

This article has been cited by other articles:

				T. Manzke, M. Dutschmann, G. Schlaf, M. Morschel, U. R. Koch, E. Ponimaskin, O. Bidon, P. M. Lalley, and D. W. Richter Serotonin targets inhibitory synapses to induce modulation of network functions Phil Trans R Soc B, September 12, 2009; 364(1529): 2589 - 2602. [Abstract] [Full Text] [PDF]

				U. Guenther, T. Manzke, H. Wrigge, M. Dutschmann, J. Zinserling, C. Putensen, and A. Hoeft The Counteraction of Opioid-Induced Ventilatory Depression by the Serotonin 1A-Agonist 8-OH-DPAT Does Not Antagonize Antinociception in Rats In Situ and In Vivo Anesth. Analg., April 1, 2009; 108(4): 1169 - 1176. [Abstract] [Full Text] [PDF]

				X. Wang, O. Dergacheva, H. Kamendi, C. Gorini, and D. Mendelowitz 5-Hydroxytryptamine 1A/7 and 4{alpha} Receptors Differentially Prevent Opioid-Induced Inhibition of Brain Stem Cardiorespiratory Function Hypertension, August 1, 2007; 50(2): 368 - 376. [Abstract] [Full Text] [PDF]